Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

420
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
420
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.1K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

1.2K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Allosteric Interactions of Flavonoids with ACE2 and Potential Implications for COVID-19: Computational Insights, Metabolic and Mitochondrial Effects of Rutin in A549 Cells.

Cell biochemistry and biophysics·2026
Same author

Evaluation of the Potency of Repurposed Antiretrovirals in HBV Therapy: A Narrative Investigation of the Traditional Medicine Alternatives.

International journal of molecular sciences·2025
Same author

Mechanisms of H2pmen-Induced cell death: Necroptosis and apoptosis in MDA cells, necrosis in MCF7 cells.

Heliyon·2024
Same author

Assessing the Potential Contribution of In Silico Studies in Discovering Drug Candidates That Interact with Various SARS-CoV-2 Receptors.

International journal of molecular sciences·2023
Same author

Epigenetic Induction of Secondary Metabolites Production in Endophytic Fungi <i>Penicillium chrysogenum</i> and GC-MS Analysis of Crude Metabolites with Anti-HIV-1 Activity.

Microorganisms·2023
Same author

Unveiling the Inhibitory Potentials of Peptidomimetic Azanitriles and Pyridyl Esters towards SARS-CoV-2 Main Protease: A Molecular Modelling Investigation.

Molecules (Basel, Switzerland)·2023

Related Experiment Video

Updated: May 9, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.2K

Computational Approaches for PPARγ Inhibitor Development: Recent Advances and Perspectives.

Ayanda M Magwenyane1, Hezekiel M Kumalo2

  • 1Chemistry Department, Faculty of Applied and Health Sciences, Mangosuthu University of Technology, Durban, 4031, South Africa.

Chemistryopen
|May 6, 2025
PubMed
Summary

Computational modeling accelerates the discovery of peroxisome proliferator-activated receptor gamma (PPARγ) inhibitors for metabolic disorders and cancer. These methods improve drug candidate design and understanding of binding mechanisms, though ADME prediction needs refinement.

Keywords:
PPARγcomputational modelsinhibitors

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.4K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

292

Related Experiment Videos

Last Updated: May 9, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.2K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.4K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

292

Area of Science:

  • Medicinal Chemistry
  • Computational Biology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARγ) inhibitors are vital for treating metabolic disorders, cancer, and inflammatory diseases.
  • Developing effective PPARγ inhibitors requires efficient identification and optimization strategies.

Purpose of the Study:

  • To review the pivotal role of computational modeling in advancing PPARγ inhibitor development.
  • To highlight how computational techniques streamline the discovery and evaluation of novel drug candidates.

Main Methods:

  • Molecular docking for predicting ligand-receptor interactions.
  • Quantitative Structure-Activity Relationship (QSAR) studies for correlating chemical structure with biological activity.
  • Molecular dynamics simulations for analyzing protein-ligand complex stability and conformational changes.

Main Results:

  • Computational modeling significantly enhances the efficiency and accuracy of PPARγ inhibitor design.
  • These methods provide deeper insights into PPARγ binding mechanisms and dynamics.
  • Ligand-receptor complex stability can be effectively predicted and optimized.

Conclusions:

  • Computational modeling has revolutionized PPARγ inhibitor discovery and development.
  • Further refinement of models, especially for predicting ADME properties, is necessary for clinical success.
  • Integration with experimental validation and new technologies will drive future advancements.